Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the dose-response of three different dose levels
of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in
patients with chronic stable angina.